

jc872 U.S. PTO
09/836697
04/16/01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: SIFFERT, W. Group: Not yet assigned
 Application No.: Not yet assigned Examiner: Not yet assigned
 Filed: Herewith
 (Continuation of 09/180,783 – Filed: 16 November 1998)
 For: THE USE OF A GENETIC MODIFICATION IN THE GENE FOR
 HUMAN G PROTEIN β 3 SUBUNIT FOR THE DIAGNOSIS OF
 DISEASES

CERTIFICATE OF MAILING

I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. EL565099793US in an envelope addressed to Box Patent Application Assistant Commissioner of Patents, Washington, D.C. 20231.

Date: 16 April 2001



Nicole M. Gignac

Assistant Commissioner for Patents
 Washington D.C. 20231

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, References CA - CG, cited in the attached Form PTO-1449.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

X

- (1) within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or

In re application of:
Application No.:
Filed:

SIEVERT, W.
Not yet assigned
Herewith

Group: Not yet assigned
Examiner: Not yet assigned

- (2) within three months of the mailing date of the PCT International Search Report; or
- (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$240.00**, is included herein; or
- (4) after the mailing date of a **Final Rejection or Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached Form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

- are enclosed herewith; or
- have been cited in the parent application, and are thus not being resubmitted herein.


FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments should be credited to said Deposit Account.

Date: 16 April 2001

Customer No.: 26770

Respectfully submitted,



David S. Resnick (Reg. No. 34,235)
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110
(617) 345-6057

In re application of:
Application No.:
Filed:

SIFFERT, W.
Not yet assigned
Herewith

Group:
Examiner:

Not yet assigned
Not yet assigned

PTO
c872 U.S. 836697
04/16/01

Sheet 1 of 1

FORM PTO-1449		DOCKET NO.: 741135-000010	SERIAL NO.: Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Siffert, W.	
		FILING DATE: Herewith	GROUP NO.: Not Yet Assigned

UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	INVENTOR/ASSIGNEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CA 1	Cotton, R.G.H. "Current Methods of Mutation Detection" <i>Mutation Research</i> 285:125-144 (1993).
CB 2	Levine et al., "Molecular Cloning of Beta3 Subunit, a Third Form of the G Protein Beta-Subunit Polypeptide" <i>Proc. Natl. Acad. Sci.</i> 87:2329-2333 (1990).
CC 3	Siffert et al., "Enhanced G Protein Activation in Immortalized Lymphoblasts From Patients with Essential Hypertension" <i>J. Clin. Invest.</i> 96:759-766 (1995).
CD 4	Kato et al., "G Protein β3 Subunit Variant and Essential Hypertension in Japanese" <i>Hypertension</i> 32:935-938 (1998).
CE 5	Brand et al., "The 825 C/T Polymorphism of the G-Protein Subunit β3 Is Not Related to Hypertension" <i>Hypertension</i> 33:1175-1178 (1999).
CF 6	Town, et al., "Alzheimers Disease is not Associated with the Hypertension Genetic Risk Factors PLA ₂ or G Protein β3, Either Independently or Interactively with Apolipoprotein E" <i>Amer. J. of Med. Genetics</i> 88:465-468 (1999).
CG 7	Fogarty et al., "The C825T Polymorphism in the Human G-Protein β3 subunit gene is not Associated with Diabetic Nephropathy in Type I Diabetes Mellitus" <i>Diabetologia</i> 41:1304-1308 (1998).

EXAMINER:	DATE:
-----------	-------